

TRANSMITTAL FORM <small>(to be used for all correspondence after initial filing)</small>	Application Number	10/507,081	
	Filing Date	September 9, 2004	
	First Named Inventor	Nicholas John Newcombe	
	Art Unit	1624	
	Examiner Name	Deepak R. RAO	
Total Number of Pages in This Submission	4	Attorney Docket Number	056291-5178

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input checked="" type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD <div style="border: 1px solid black; padding: 2px; width: fit-content;">Remarks</div>	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 1. Submission of Replacement Terminal Disclaimer

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Morgan Lewis & Bockius LLP		
Signature			
Printed name	Donald J. Bird		
Date	January 10, 2008	Reg. No.	25,323

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:)	Confirmation No. 2669
)	
NEWCOMBE <i>et al.</i>)	
)	
Application No.: 10/507,081)	Group Art Unit: 1624
)	
Filed: September 9, 2004)	Examiner: Deepak R. RAO
)	
FOR: DERIVATIVES OF 4-(IMIDAZOL-5-YL)-2-)	
(4-SULFOANILINO) PYRIMIDINE WITH)	
CDK INHIBITORY ACTIVITY)	
)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: January 10, 2008

Sir:


SUBMISSION OF REPLACEMENT TERMINAL DISCLAIMER

Submitted herewith is a corrected Terminal Disclaimer which is to **replace the Terminal Disclaimer** filed herein on November 19, 2007. It has just been brought to the attention of the undersigned that the Terminal Disclaimer filed November 19, 2007 inadvertently and incorrectly listed the assignee of the present application as AstraZeneca UK Limited, whereas this application is actually assigned to AstraZeneca AB. The replacement Terminal Disclaimer submitted herewith corrects this error.

It is understood by analogy to MPEP § 1490.V.C. that no additional fee is required for this replacement Terminal Disclaimer, but if a further fee is required authorization to charge such fee is included below. It is respectfully requested that the Examiner, in the next Action, acknowledge that this substitute Terminal Disclaimer has replaced the first-filed terminal disclaimer of November 19, 2007, which is thus void.

EXCEPT for issue fees payable under 37 C.F.R. § 1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§ 1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. § 1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP



Date: January 10, 2008
Morgan Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:

By:

Donald J. Bjrd
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001